Leqembi, Cost Cuts Propel Biogen's Profit Outlook Despite MS Sales Decline

Biogen anticipates a rise in profits due to its Alzheimer's drug Leqembi and cost-cutting measures, despite a projected decline in revenue from its multiple sclerosis treatments, which have seen significant sales drops.